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Multiple synchronous (multifocal or multicentric) ipsilateral breast cancers with heterogeneous
histopathology are a rare clinical occurrence, however, their incidence is increasing due to the use of
MRI for breast cancer screening and staging. Some studies have demonstrated poorer clinical outcomes
for this pattern of breast cancer, but there is no evidence to guide clinical practice. In this multidisciplinary
review, we reflect on pathology and molecular characteristics, imaging findings, surgical management in-
cluding conservation and reconstructive options and approach to the axilla, and the role of chemotherapy
and radiotherapy. Multidisciplinary discussions appear decisive in planning an appropriate surgical choice
and defining the correct systemic treatment tailored to each clinical condition.
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Multiple synchronous (multifocal or multicentric) ipsilateral breast cancers (MSIBC) with heterogeneous
histopathology represent a rare clinical conundrum. Breast cancer (BC) is now defined not only by histologi-
cal but by molecular characteristics reflected in the new TNM prognostic staging [1], so tumors with different
morphological and molecular profiles in the same patient introduce challenges in therapeutic decision-making.
Clear treatment guidelines for this difficult subset of BC are not described in the literature due to the low clinical
frequency.
One of the key decisions in this group of patients regards medical therapy, and whether to deliver this in
the adjuvant or neoadjuvant setting. BC adjuvant therapies are defined in accordance with estrogen receptor
(ER), progesterone receptor (PgR) and HER2 status; endocrine therapy is indicated for ER and PgR-positive BC,
chemotherapy is classically recommended for triple-negative BC with a move toward platinum-based regimes, and
HER2-positive tumors receive HER2-targeted agents in conjunction with chemotherapy. In the case of hetero-
geneous BC, the nature and timing of medical therapy is extremely important to facilitate surgical downstaging,
avoid breast recurrence and improve prognosis.
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There is often discussion regarding the optimal breast surgical approach and whether breast conservation surgery
(BCS) rather than mastectomy is appropriate. When the tumor affects breasts bilaterally, patients are often treated
with mastectomy, with BCS having an as yet unclear role [2]. There is no significant difference in survival for
patients with bilateral BC compared with unilateral tumors [3], however, synchronous tumors are associated with
poorer survival in comparison to metachronous tumors [2]. In this multidisciplinary review, we propose a clinical
management for MSIBC with heterogeneous histopathology.
Tumor heterogeneity & cancer genetics
Historically, MSIBC were defined as multicentric when they occurred in different quadrants and multifocal when
they were in the same quadrant; due to inconsistencies in defining these terms and their lack of functional anatomical
relevance, this has been replaced with the term ‘multiple BCs’ [4,5]. In histological terms, BC is defined as multiple
when it consists of more than one well distinguished tumor foci separated by normal or benign breast tissue or by
intervening Ductal Carcinoma In Situ (DCIS) [6]. The American Joint Committee Cancer (AJCC) tumor node
metastasis (TNM) staging system defines tumor size as the size of the single largest focus of MSIBC [5].
Some authors support the hypothesis that MSIBC tumors are best represented by the aggregate dimension that
reclassifies tumors to a more advanced stage [7]. In the literature, the incidence of MSIBC varies from 6–77%, and is
dependent upon both use of imaging modalities such as MRI and the thoroughness of histological sampling [4,6]. In
patients affected by T1-T2N0-1 BC, MSIBC were found in 21% of mastectomy specimen in a study from the
MD Anderson Cancer Center [8]. There are two main theories as to how multiple tumor foci arise in the same
breast that are not mutually exclusive: they represent local in breast metastasis arising from a single primary lesion,
or they have arisen independently and represent true separate primary lesions. It can be challenging using standard
morphological characteristics alone to determine which cases represent true synchronous primary tumors and which
are in breast metastases originating from a single primary.
Histologic BC classification is performed in accord with the morphologic heterogeneity of BC. Invasive ductal
cancer (IDC or no special type) is the most common histologic type of invasive BC (40–75%) [9]. Moreover, there
are 21 special subtypes of BC defined by the WHO in 2012, and invasive lobular cancer (ILC) is the most frequent
(15%). The other BC special subtypes are rarely diagnosed and with great differences in relation to prognosis
and response to adjuvant treatment [10–13]. Papillary, mucinous and tubular carcinomas usually show the best
outcomes, instead metaplastic carcinoma and poorly differentiated IDC have worse prognosis that often require
more aggressive systemic treatments [14]. Several series looking at MSIBC have been published in the literature; in
5–37% of cases the tumor deposits are of different histological subtypes, and in 6–30% the foci are of different
grade [6,15–17].
In terms of biomarker expression, ER is discordant in 2–12% of cases, PgR in 11–19% and HER2 is different
in 2–16% [6,15–20]. Looking at combined receptor expression to give molecular subtype, this was discordant in
6–13% of cases [6,15,17]. Differences in ER and HER2 expression are often associated with differences in tumor
morphology, however, Buggi et al. specifically looked at tumors with similar histology and found ER was discordant
in 4% and HER2 in 10%, resulting in a change in therapy in 12% of patients [21]. Gene expression profiling is
now used in predicting benefit from chemotherapy, particularly in ER-positive HER2-negative disease. One series
found a difference in the Oncotype Dx 21 gene recurrence score (RS) in 4/18 ipsilateral tumor foci that would
have resulted in a difference in recommendation for chemotherapy [22].
In patients with concordant scores tumor histology and grade differed in 18.8 and 6.3% of cases, respectively,
as compared with 66.7 and 50% of cases for those with discordant scores (p = 0.05 and 0.04 for tumor histology
and grade, respectively). Although not statistically significant, tumors with different RS were also more likely to
differ in PgR status (33.3 vs 18.8%). Patients with accordant scores presented tumor histology and grade different
in 18.8 and 6.3% of cases, respectively, as compared with 66.7 and 50% of cases for those with discordant scores
(p = 0.05 and 0.04 for tumor histology and grade, respectively). PgR status appeared likely different in tumors with
unlike RS (33.3 vs 18.8%), although without statistical significance. This is clinically important, as current AJCC
guidelines recommend testing of the largest focus only unless the smaller foci are of different grade or histological
subtype [1]. A more recent retrospective trial demonstrated that RS were discordant in 33% of women with ER-
positive, HER2-negative, node-negative, synchronous bilateral invasive BC, leading to a change in treatment in
57% of these patients. Discordance in RS was demonstrated in a more recent retrospective trial demonstrated that
RS were discordant in 33% of women with ER-positive, HER2-negative, node-negative, synchronous bilateral
invasive BC, causing a change in treatment in 57% of these patients. There is far less in the literature looking at the
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underlying genetic differences in multiple synchronous breast cancers. Biermann et al. found that four of eleven
cases of synchronous ipsilateral breast cancers were of different intrinsic subtype; one of these was also of different
histological subtype with IDC and lobular foci [23].
The authors also undertook molecular analyses using array-based comparative genomic hybridization, methyla-
tion, gene expression and RNA sequencing and found 4/11 cases were independent and 7/11 were of clonal origin;
interestingly three quarters of cases were independent on both clinical and molecular characteristics, while one case
was discordant histologically but showed similar molecular features, while another was discordant on molecular
but not histological characteristics.
While being of different subtype is a clear indicator of separate synchronous primary tumors, as over 70% of
invasive BCs are classified as IDC having the same morphology does not conversely mean that tumors are clonally
related. Desmedt et al. looked at a series of 36 patients with multiple invasive ductal carcinomas with the same
grade and hormone receptor (HR) status using a targeted sequencing approach, and found roughly a third of cases
had the same mutation profile, a third had shared mutations indicating common clonal origin but also had private
mutations in different foci, and a third had no shared mutations [24]. The tumors without any common mutations
were situated further apart than those with shared driver mutations, although the difference did not reach statistical
significance. Of note, despite there being no shared mutations, shared copy number changes were found between
lesions suggesting deeper interrogation with tools such as whole-genome sequencing may find evidence of shared
subclones with clonal divergence in a greater proportion of cases. One series examining tumoral heterogeneity
using whole genome and targeted sequencing approaches included samples from four multiple ipsilateral tumors
and found all foci examined were clonally related, with additional subclonal driver events and intermingling of
subclones across foci [25]. Invasive lobular carcinoma is reported as being more commonly multifocal. Another series
showed similar copy number changes but variation in gene expression between multiple foci of invasive lobular
carcinoma from the same patient [26]. These results are significant in that taking biopsy samples for molecular
studies to determine eligibility for clinical trials is becoming increasingly common, and in the case of multiple
tumors a sample from the main lesion may miss genetic heterogeneity across foci even if morphologically similar.
In some studies MSIBC have been found to correlate with known risk factors suggestive of aggressive biology, such
as young age, higher grade, HR status, HER-2 status, lymphovascular invasion (LVI) and nodal involvement [17,27].
Other factors may also play a role, such as the loss of E-cadherin, which causes disconnection of cell–cell adhesion
and contributes to metastatic potential. A recent study by Weissenbacher et al. demonstrated that MSIBC had
significant downregulation in the expression of E-cadherin versus unifocal (UF) lesions [28].
Imaging
BC typically presents as a spiculated, oval, lobulated hyperdense lesion, with or without microcalcifications, on
mammography, and as an ill-defined/spiculated, hypoechoic or inhomogeneously hyperechoic mass with posterior
acoustic shadowing on ultrasound. On MRI, BC is seen as an isointense to hypointense mass on T1- and T2-
weighted images, with early contrast-enhancement, washout and restriction of water signal on diffusion-weighted
imaging.
Radiological features of BC may vary greatly; these differences often depend on tumor grade and histological
subtype. Hence, sometimes differences in imaging characteristics can predict differences in tumor morphology
and biology. ILC frequently invades the normal tissues without invoking the vigorous desmoplastic response that
is usually seen in IDC. As a result, the density of ILC is often similar to that of background normal breast
fibroglandular tissue, making it mammographically occult [29,30]. Changes can be very subtle, such as progressive
shrinkage or enlargement or reduced compressibility of the involved breast [29]. Invasive lobular breast cancer is often
multicentric (10–15%), and multiplicity appears more correlated with ILC compared with other histotypes [29].
Due to the limitations of mammography in delineating ILC and the risk of underestimation, other modalities such
as sonography and MRI are used to assess the extent of disease [31].
The most common MRI presentation of ILC is that of a mass-like enhancement with irregular or spiculated
margins, with rapid uptake and late washout. It may also present as a nonmass-like enhancement with ductal,
segmental, regional or diffuse pattern [32].
Preoperative lymphoscintigraphy & the role of sentinel lymphnode biopsy
Axillary lymph node staging is also part of the surgical management in MSIBC. BC with multicentric spreading has
been considered a relative contraindication to sentinel node biopsy (SNB) due to a presumed higher risk of nodal
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involvement compared with UF BC and concerns that the location of these tumors in different quadrants of the
breast might involve more than one dominant lymphatic trunk [33,34]. Therefore, the optimal route of radiocolloid
injection has been widely debated, with several different approaches reported in the literature. As a result of these
concerns, some researchers have argued that a central injection with a subareolar or periareolar technique may be
beneficial. The rationale was based on early studies on the lymphatic system of the breast, in particular on the work
of Sappey (1874), a French anatomist.
The author observed that breast lymphatic drainage originated as an intense structure around the lobular
glands, and forming subsequently lymphatic trunks alongside the breast ducts centripetally since to the periareolar
complex and finally to the axilla [35]. Direct lymph pathways from the injection site to axillary lymph nodes were
demonstrated later by Turner-Warwick, who pointed out the possibility that Sappey had overemphasized the role
of the subareolar plexus [36]. Direct lymph tracks from the injection site to axillary lymph nodes were displayed
later by Turner-Warwick, who underlined the possibility that Sappey had overestimated the involvement of the
subareolar plexus [36]. Although there is not yet a clear and definitive understanding of the lymphatic drainage of
the breast, different studies demonstrated that it is drained uniformly to a few sentinel lymph nodes, regardless of
the injection site of the tracer.
Bauer et al. performed sentinel node mapping in 332 patients with biopsy-proven operable breast cancer or
ductal carcinoma in situ through blue dye injection (peritumoral in 83 patients and subareolar in 249 patients) and
peritumoral injection of 99mTc-labeled sulfur colloid (all patients) and concluded that the two different localization
of tracer delivery identified similar lymph nodes [37]. Klimberg et al. came to the same conclusions by injecting
99mTc-labeled sulfur colloid in the subareolar area of the tumor-bearing breast and isosulfan blue in the peritumoral
region of 68 patients with invasive BC and clinically node-negative disease [38]. Kargozaran et al. conducted an
analog study on 124 patients and showed a high degree of concordance between subareolar blue dye and peritumoral
radiocolloid identification of the sentinel node [39].
Moreover, the validity of subareolar or periareolar injection has been established in a large prospective, multicenter
clinical trial on 3961 patients with clinical stage I and II breast cancer. 348 patients had injection with blue dye
alone; of the 1762 patients who had injection of 99mTc-sulfur colloid, 1431 had a peritumoral injection while 148
and 183 had a subareolar and periareolar injection, respectively. All patients were submitted to SNB followed by
axillary dissection and there were no statistically significant difference in the false-negative rates among the groups,
supporting the hypothesis that the lymphatic drainage of the entire breast is to the same few SNs [40].
The use of SNB in multicentric BC is still debated, however, the procedure is routinely performed in patients
with clinically negative nodes in many centers, due to the evidence that its accuracy in this disease is comparable
with that of published validation studies on UF tumors [41–44]. In one series, positive lymph node involvement
was reported in 44–50% of MSIBC cases compared with 38% of UF cancers [45]. In a previous study conducted
at our Institution, among 337 patients with multicentric BC and clinically negative axilla, having negative SNB
and no axillary lymph node dissection (ALND), axillary lymph node recurrence occurred only in three patients
after a median follow-up of 5 years [43]. Given the reported data and the simplicity of execution combined with
the limited discomfort for the patients, the subareolar injection of radiolabeled colloids has become of the method
of choice for multicentric disease in our institution. The injection is performed the same day of surgery, if it is
scheduled in the afternoon, or the day before surgery, if it is scheduled in the morning. The injected activity is
15–20 MBq in a volume of 0.1–0.2 ml. Lymphoscintigraphy is then performed as described elsewhere [46]: briefly,
planar scintigraphic scans of the involved breast and axillary region, in the anterior and anterior oblique projections,
are obtained 20 min, up to 3 h if needed, after the injection of the radiocolloids. The skin projection of the first
node (or nodes) to take up tracer is marked with a suitable pen after the last acquisition.
These premises are inserted in a broader scientific context: the evolution of BC surgical treatment with the
ACOSOG Z0011 trial suggested that even patients with limited macrometastasis in the sentinel node (SN) who
were treated with breast conserving therapy, whole breast and axillary irradiation in addition to systemic treatment
could be spared an ALND, without compromising outcome [47].
Breast surgery
Breast-conserving surgery
BCS still seems to be a relative contraindication in case of MSIBC, due to the higher risk of further occult
foci in the same breast and the potential for worse cosmetic outcome subsequent to wide and multiple excisions
in the same breast [48]. Opportunities for BCS have improved recently due to the introduction of mammoplasty
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techniques, even if evidence from clinical studies on quality of life after mammoplasty in BCS (as defined by Winters
et al., ‘therapeutic mammoplasty’) compared with mastectomy is currently lacking [49]. In the literature, there are no
prospective cohort studies or randomized trials comparing BCS with mastectomy, analyzing locoregional recurrence
(LRR) as a primary end point in MSIBC: indeed, most of those are retrospective cohort studies [50].
The recent ongoing American College of Surgeons Oncology Group (ACOSOG) Z11102 prospective single-
arm trial demonstrated in its initial results that 67.6% of the women that underwent BCS for MSIBC successfully
completed surgery with negative margins, and with an acceptably low rate of conversion to mastectomy (7.1%).
Also, it did not identify any specific patient, imaging or tumor factors that predict patients at increased risk for
failure of BCS in the MSIBC population [51]. This study only enrolled patients eligible for BCS and not for
mastectomy; however, the SENOMAC study is an ongoing trial that similarly to the Z11102 protocol enroll
patients eligible for mastectomy.
BCS in MSIBC finds support in the recent expert consensus in St. Gallen, advocating the feasibility of BCS
for surgical treatment in MSIBC, with the crucial assumption of adequate margin clearance and whole-breast
radiotherapy (RT) after surgery [52,53]. For this reason, multidisciplinary discussion is vital for appropriate patient
selection for BCS in the case of MSIBC. A multidisciplinary team involving Radiologist, Oncologist Surgeon,
Medical Oncologist, Radiation Oncologist, Plastic Surgeon, Pathologist plan the surgical procedure with the aim
to obtain clear margins with the best cosmetic outcome. The choice of BCS commences with evaluation of the
ratio between composite tumor size and breast volume, in conjunction with clinical management based on history
and physical examination, accurate imaging studies and histological and biological presurgical information of every
cancerous lesion detected in the breast. Of equal importance are the patient’s needs and expectations, because BCS
represents the preferred method of treatment for many patients [54].
The technical procedure takes into account the necessity for multiple surgical excisions without causing breast
deformity and with a low re-excision rate. Tumor size and location along with histopathological and biological
features and presence of lymph node involvement will influence the choice of neoadjuvant treatment in MSIBC;
the different tumor foci need to be clipped pretreatment to ensure precise localization of the tumor bed to guide
surgical excision after primary therapy. Galimberti et al., in line with Senonetwork recommendations, advise specific
techniques and preoperative procedures should be carried out to obtain negative margins and reduce the probability
of second operations, especially in case of occult cancers. Based on single institutional experience, several procedures
including charcoal, metal wire and radioguided occult lesion localization are useful to accurately identify the cancer
site [55]. The site and performance of skin incision is also vital for the quality of cosmetic results. Curvilinear skin
incisions following Langer’s lines (the natural lines of skin tension) are a good choice to achieve the best cosmetic
outcomes, with radial incision being a better choice for cancers situated in the lower inner or external quadrants [54].
Excision of a segment of skin is rarely necessary for oncological reasons and not advisable for alteration of the nipple
and inframammary crease position.
Oncological safety should be ensured by resection of the tumor with an adequate quantity of surrounding
benign glandular tissue, and by reducing intraoperative tumor margin positivity through ‘real-time’ cancer margin
assessments. The specimen should be orientated with specific markers to enable macroscopic assessment of margins
status by the pathologist, so resection of further tissue can be performed in case of proximity of tumor to the
margins. Frozen section of margins is an option but due to sampling limitations in large oncoplastic specimens
does not guarantee negative margins [54,55], it can be a correct and safe practice, in case of MSIBC, to minimize
the need for subsequent resections, in particular after oncoplastic procedure. The margin of concern should be
clearly indicated, and the specimen should not be sectioned before it is submitted to the pathologist, as this will
compromise accurate histological evaluation of the surgical margins [54]. In case of microcalfications, postbiopsy
clips or impalpable lesions, 2D specimen x-ray should be performed [55].
Future research will have to take into consideration the genomic profile of each BC lesion in MSIBC: the
consequent similarity or heterogeneity in all the cancer foci will guide the correct choice in multidisciplinary
treatment. Furthermore, the feasibility of administering RT with boosts to one or more tumor beds after BCS
for MSIBC must be determined, as well as the impact of the extent of surgery on 10-year LRR as an outcome
measure [50]. The results of trials in progress will enrich our knowledge and provide a sound scientific background
for future management guidelines. The final data of ACOSOG Z11102, currently examining LRR following BCS
for women with MSIBC [51] and the British MIAMI trial will evaluate the safety of oncoplastic procedures (BCS
associated with mammoplasty) in MSIBC [45]. However, the limitation of this study enrolled only 50 patients. The
Z11102 study only enrolled patients eligible for BCS and not for mastectomy; however, the SENOMAC study is
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a novel ongoing trial that similarly to the Z11102 protocol enroll patients eligible for mastectomy. The MIAMI
trial is also ongoing.
Oncoplastic surgery
Nowadays, oncoplastic surgery is a well-established approach that combines conserving treatment for BC [56–58]
and plastic surgery techniques [59]. It allows wide excisions and prevents breast deformities by the immediate
reconstruction of large resection defects [60,61]. Currently, oncoplastic surgery is a steady procedure that joins
conserving therapy for BC [56–58] and plastic surgery techniques [59]. It enables wide resections and avoids breast
deformities by the immediate reconstruction of consequent defects [60,61].
The cosmetic advantages of this approach have been largely described [62]. Moreover, oncoplastic surgery achieves
more accurate tumor resection and free resection margins than standard quadrantectomy or lumpectomy [63,64]
and it is definitively useful in extending the indications for breast conservation even in synchronous multicentric
BCs [65]. In addition, if a contralateral reduction mammaplasty is performed to achieve similar breast size after large
quadrantectomy and reshaping, a ‘surgical screening’ of the contralateral healthy breast may allow the diagnosis of
occult cancers [66].
Among the full range of oncoplastic techniques, there are two fundamentally different approaches: volume-
replacement procedures, which combine resection with immediate reconstruction by using local flaps (glandular,
fasciocutaneous and latissimus dorsi miniflaps); and volume-displacement procedures, which combine resection
with a variety of different breast reduction and reshaping techniques, according to the location of the tumor. Among
the all choices of oncoplastic techniques, there are two fundamentally diverse approaches: volume-replacement
procedures, which match resection with immediate reconstruction by using local flaps (glandular, fasciocutaneous
and latissimus dorsi miniflaps); and volume-displacement procedures, which combine resection with different
breast reduction and reshaping techniques, based on the site of the tumor [67]. Both approaches may be performed
in case of synchronous multicentric cancers according to tumor size and location and breast size. The ratio of
tumor size:breast size is a key point and surely influences the choice between breast conservation and mastectomy.
Synchronous multicentric cancers in small breast are treated by mastectomy that represents the gold standard. In
fact, local flaps (glandular or fasciocutaneous) are inadequate to reconstruct large quadrantectomy defects resulting
in unsatisfactory results and breast asymmetries. Locoregional flaps, such as latissimus dorsi or perforator flaps,
from the dorsal region might correct large defects in small breasts but they are not frequently performed since they
require more extensive and sophisticated dissection, longer operative time and additional scarring in the donor area.
Synchronous multicentric cancers in large breast are frequently treated by oncoplastic approaches. Several
reduction techniques, upper or inferior pedicled or through a round-block periareolar approach, may be indicated
bilaterally according to cancer location. In those patients, early complications affected more frequently the breast
with cancer than in the healthy breast, as infection, seroma formation and wound dehiscence, due to the more
complex surgical approach and the more extensive surgery (including axillary SNB or complete axillary dissection
– three levels). However, local complications at the cancer site do not negatively influences delivery of adjuvant
treatment as reported by most studies comparing oncoplastic versus conservation alone, showing no difference in
surgical complications between the two groups [67].
Although any publication has specifically investigated the outcomes of synchronous multicentric breast cancers
treated by oncoplastic surgery, about 25% of patients with synchronous multifocal cancers are included in the two
series published by De Lorenzi et al. [68]. The first study compares a consecutive series of 454 patients who have
undergone oncoplastic (ONC) with 908 patients who have undergone conservation alone (control group) over
a prolonged period of time at one institution. The authors conclude that ONC is a safe and reliable treatment
option for the managing of invasive BC. In the second paper [68], a series of 193 T2-patients who have undergone
oncoplastic surgery were compared with 386 T2-patients who have undergone mastectomy over a prolonged period
of time. Overall survival (OS) and disease-free survival are similar within the two groups. The authors conclude
that the study provides the best available evidence to suggest that ONC approach is a safe and reliable treatment
for managing invasive pT2 breast cancers.
Mastectomy
In the so-called nipple-sparing mastectomy (NSM) process, the breast tissue anatomically localized by splitting of
the superficial fascia delimited by the large infraclavicular muscle bundle, the midline of the sternum, the front edge
of latissimus dorsi and the lower edge of major pectoralis on the sixth rib should be removed en bloc. The patient
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must be informed of residual cancer risk from remaining glandular cells even in the most accurate mastectomies.
Respecting the limits of the dissection and saving the inframammary folds allow a better breast reconstruction.
Several skin incisions have been proposed in the literature in order to remove en bloc the glandular breast tissue
on the one hand, and maintaining the entire breast envelope on the other. The upper outer linear incision is
most commonly used because it safeguards vascularization of the nipple areola complex and easily removes all the
glandular tissue. However, it is not the right cosmetic approach for every patient, and consideration must be given
that during healing, the scar could retract the nipple areola complex toward the axillary tail. Moreover, there are
also nonconventional surgical approaches tailored to the individual patient [69], when the classic incision is not
possible [70].
Technical innovations have already made feasible robotic NSM, and this has been reported as well tolerated, safe
and associated with good cosmetic outcomes. The robotic technique reproduces the open approach, and assisted by
the accuracy, flexibility and control given by the robot allows the surgeon to perform complete mastectomy through
a tiny hidden extramammary incision [71,72]. A randomized clinical trial comparing open NSM and robotic NSM
in prophylactic surgery is on going (clinicaltrials.gov number NCT03440398). However, patients with moderate
and/or severe breast ptosis are usually not eligible for this classic surgical approach for NSM. Different patterns for
skin incisions are classified as hemi-periareolar, round block, vertical pattern and wise pattern approaches [73]. The
selection criteria for NSMs include: no areolar or nipple retraction; no nipple discharge-containing blood; no
inflammatory disease and negative intraoperative retroareolar margins on frozen sections. Multicentric disease is
not a contraindication.
SNB is indicated in case of mastectomy in patients with clinically negative nodes, and ALND still represents the
standard treatment in cases of macrometastases that affect any SN. Instead, in the case of SN with micrometastasis
and/or isolated tumor cells, ALND is not indicated. The IBCSG 23-01 multicenter, randomized, noninferiority,
Phase III trial, enrolled 465 patients randomly assigned to ALND and 469 to no ALND. Patients had one or more
SNs with micrometastases. The IBCSG 23-01 trial published recently the results from 10 years of observation.
This study has confirmed that ALND is not indicated in patients with micrometastatic SNs [74].
The SENOMAC trial is a new ongoing multicenter noninferiority study. The hypothesis of this trial is ‘no
axillary clearance in BC patients with one to two SNs with macrometastasis will not worsen BC-specific survival.’
About 3500 patients will enrolled for this study (in press), and the trial will closed in December 2022.
Mastectomy with breast reconstruction
Options for postmastectomy reconstruction include implant-based reconstructions and autologous tissues [75]. The
reconstruction is usually performed at the same time of mastectomy and called ‘immediate.’ Rarely, it is postponed
in a second surgery (delayed reconstruction). The type of mastectomy (skin sparing or nipple-areola sparing), breast
size and surgical skin incisions impact on the type of reconstruction, as well as patient demand and co-morbidities.
Plastic surgeons need to deal with different issues, tailoring patient therapeutic strategies. Unfortunately, not all
women are suitable for nipple–areola sparing mastectomy. To reduce possible complications, as mastectomy flap
necrosis, and to improve cosmetic outcome, skin sparing mastectomy is more indicated for patients with large (D
cup or larger) ptotic breast or in cases of multiple previous scars [76–78].
Implant-based reconstruction
The improved manufacture of implants associated to the development of new surgical techniques raised the
popularity of implant-based breast reconstruction. The main advantages are short operative time, no donor site
morbidity and less recover time. However, implant is not a lifelong medical device [79]. The main advantages are
brief operative time, no donor site morbidity and minor recover time. However, implant is not a permanent medical
device [79] and patients must be informed about revisional surgery and implant-related complications.
One-stage implant reconstruction
This is probably one of the simplest and effective procedure of immediate reconstruction supposing that the
surgeon selects a good candidate and implant model [80]. This is probably one of the simplest and valid procedure of
immediate reconstruction presuming that the surgeon chooses a good candidate and implant model [80]. Anatomical
silicone gel implants are usually used to mimic the natural shape of the breast.
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Two-stage (expander–implant) implant reconstruction
In the first stage, a tissue expander is placed in the muscular pocket, behind the pectoralis major muscle and the
serratus anterior muscle or its fascia. The tissue expander is partially filled with saline solution. The injection port
is usually integrated on the expander surface, the old models had a distant port. The expansion usually starts
2–3 weeks postoperatively, then every few weeks until the final volume is reached, which is usually slightly bigger
than the definite prosthesis. Expander–implant change is planned few months after primary surgery depending
on postoperative adjuvant treatments. For instance, such as prolonged medical or chemotherapy or pregnancy-
associated breast cancer, it can be substituted over the year [81].
The expansion usually starts 2–3 weeks postoperatively, then every few weeks until the final volume is obtained,
which is usually slightly bigger than the definite prosthesis. Expander–implant change is projected few months after
primary surgery related to postoperative adjuvant treatments. For instance, in the case of adjuvant chemotherapy
or prolonged medical treatments, or in the presence of breast cancer associated with pregnancy, it can be replaced
over the year [81].
Autologous tissue reconstruction
Many patients prefer autologous reconstruction, if possible, because of the similarity to natural breast, stability
overtime of the long-term result and the anxiety about using foreign material/implants. Autologous reconstruction
encompasses a broad range of procedures incorporating the patient’s own tissues to recreate the breast mound
(pedicled and free flaps, fat grafting). On the contrary, these techniques require significantly long surgical time and
they are associated to increased donor-site morbidity [82].
There are various types of autologous reconstructions:
• Pedicled transverse rectus abdominis musculocutaneous flap;
• Free transverse rectus abdominis musculocutaneous flap;
• Deep inferior epigastric perforator flap;
• Latissimus dorsi flap.
In case of unilateral mastectomy for MSIBC, autologous reconstructions allow better cosmetic results. In fact,
unilateral implant reconstruction generally fails to fully ‘match’ the contralateral breast without a bra and over
time this asymmetry actually worsen as the contralateral natural breast becomes more ptotic and changes in size
with patient weight gain or loss. On the contrary, bilateral reconstructions with implants may be really satisfactory,
especially in case of small to medium breasts when nipple and areola are preserved. The differences in the long term
with both options (implants or autologous tissues) are not significant [83].
The complication rates after reconstruction vary considerably, 8–64% in the literature [84]. This may depend
on patient selection or the definition of complications. There is no consensus on what should be considered a
complication. The most common complication is early wound necrosis/epidermolysis usually involving the nipple–
areola complex or skin edges, sometimes leading to implant loss [85]. In addition, late complications concern cosmetic
issues, almost always leading to additional surgery. In this respect, patients should be informed preoperatively that
an optimal cosmetic reconstruction cannot unconditionally be achieved in just one single operation.
The late complications regard cosmetic questions and often require additional surgery. In this contest, the patient
should always be informed preoperatively of the uncertainty of obtaining an optimal cosmetic result in a one single
operation. Late complications include also those related to silicone breast implants, as recent scientific reports
suggest their possible role in chronic stimulation, autoimmune response and subsequent risk of developing a breast
implant associated-anaplastic large cell lymphoma.
Adjuvant treatments
Approach at BC treatment is based on clinical stage, histopathology and biomarker pattern [14,86]. Also, menopausal
status, age at onset and health status influenced treatment’s choice. These factors are related significantly with survival
and explain most of the variations observed in clinical outcomes among patients with BC. Overviews by the Early
BC Trialists’ Collaborative Group have well recognized the benefit of adjuvant polychemotherapy in early BC
patients irrespective of age, the use of tamoxifen, HR status, nodal status and other tumor characteristics, reducing
the annual odds of disease recurrence and BC mortality [87]. In addition, these overviews have also shown a reduction
in the risk of BC mortality by approximately a third with the use of adjuvant endocrine therapy in patients with
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ER-positive BC regardless of PR status, age, nodal status and the use of chemotherapy. Given the growing knowledge
treatments were assessed in light of their intensity, duration and side effects, seeking where appropriate to escalate
or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology.
Due to the growing knowledge, treatments have been evaluated in relation to their intensity, duration and side
effects, trying, if necessary, to intensify or reduce the therapies based on probable benefits, as foreseen by the
tumor stage and biology. In the setting of MSIBC, the choice of the best adjuvant treatment may appear simple.
However, currently, there are no consistent evidence-based guidelines for the management of MSIBC, and treatment
decisions are often made based on the primary tumor with the most high-risk features. However, currently there are
no substantial evidence-based guidelines for the management of MSIBC and therapeutic decisions are often based
on the most high-risk characteristics of the primary tumor. This could be particularly true for different tumors with
different biology, but in case of multicentric ER-positive, HER2-negative, node-negative BC, this distinction may
be difficult as the tumors may appear quite similar by standard histopathologic criteria. Gene expression signatures
such as the 21-gene RS have been demonstrated to predict chemotherapy benefit in this group of patients, and as
discussed in adjuvant treatments this may be different in up to 22% of MSIBC, particularly if the tumor foci are
of different grade or histological type [22].
It is well known that heterogeneity is a hallmark of malignancy; it can be appreciated within a single tumor or
between primary breast carcinomas and synchronous lymph node metastases. This aspect should be particularly
underlined in case of MSIBC with different biology and positive nodes at diagnosis. The status of the axillary lymph
nodes is the most important single prognostic factor for patients with BC and the correct biological characterization
of the node metastases can help the clinicians to choose the most appropriate treatment. In particular, this aspect
could be crucial in the decision-making process as to whether or not to give neoadjuvant chemotherapy. The
association of adjuvant systemic therapy with improved survival is clearly demonstrated.
However, Mauri et al. did not find any difference in OS, disease progression and distant disease recurrence
between neoadjuvant and adjuvant treatment in a meta-analysis of nine trials with around 4000 patients [88]. In
relation to the scientific evaluation of therapeutic benefits of neoadjuvant treatment, research could find future
potential opportunities in two promising prospects:
• In vivo assessment of therapeutic efficacy, obtaining important prognostic and predictive information based on
the response to treatment, the analysis of the extent and characteristics of the residual disease and the identification
of biomarkers of drug sensitivity and resistance;
• Accelerated approval of new drugs [89,90].
Randomized trials of chemotherapy demonstrate similar long-term outcome when patients receive the same regimen
preoperatively compared with postoperatively. A recent meta-analysis demonstrated that complete pathological
response decreased with the increasing of clinical tumor size (trend p < 0.0001) in particular in cases of ER-
negative tumors than in those ER-positive (p < 0.0001) and in poorly differentiated tumors than in well or
moderately differentiated (trend p = 0.001). Furthermore, complete pathological response was higher in the one
trial that associated anthracycline and taxane drugs than in the other trials (p < 0.0001). Age, nodal status and
planned local therapy did not related with response [91]. Patients with MSIBC are not always eligible to participate
in neoadjuvant clinical trials, however, the histological confirmation of at least two lesions could be considered and
this attitude should be also used in clinical practice. In case of patients with multicentric tumors with different
biology and with positive axillary nodes, the assessment of biology on the lymph nodes should also be considered.
Radiotherapy
The efficacy of whole breast irradiation in MSIBC disease
Whole breast irradiation (WBI) after BCS has been proven to be effective against residual microscopic foci of BC,
as evidenced by the fact that omission leads to an increased local recurrence (LR) rate of up to 39.2% in historical
landmark trials [91,92]. LRs occur mainly at or near the original tumor bed but distant quadrants can also be affected
with incidence as high as 42%, especially in young patients [93]. Whatever the clinical and biological significance
of occult foci of cancer, the overall effect of WBI is satisfactory in terms of local control, achieving rates as high as
94% at 10 years for stage I–II disease [94,95]. Nowadays, thanks to advance in diagnostic imaging, often including
magnetic resonance, MSIBC have become more clinically apparent. BCS might remain a feasible option as long as
it abides by the principles of oncological clearance.
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In MSIBC, BCS raises a series of issues for radiation oncologists. First, oncoplastic techniques involving tissue
translocation are frequently applied in this setting [96], making the location of the original tumor difficult. Therefore,
a higher dose to the tumor bed might be not properly delivered and its omission could increase the risk of local
relapse, especially in young women and grade 3 tumors, where the use of boost significantly impacts on local
control [97]. Second, concerns regarding the increased risk of moderate to severe fibrosis to a large breast volume
receiving the boost dose [98] in the attempt to cover the entire area of MSIBC, potentially resulting in worse cosmetic
outcomes. In addition, MSIBC called into question the overall efficacy of WBI after BCS. Some authors reported
negative results when BCS is performed for macroscopically MSIBC [99,100], based on the fact that the neoplastic
residual burden was considered so great that WBI could not control it. Chung et al. recently investigated a cohort
of MSIBC patients undergoing BCS and found that both relapse-free survival and OS were significantly reduced
in the group of MSIBC compared with UF BC [101].
Similarly, in a pair case–control cohort [102], the long-term actuarial local control rates for MSIBC and UF tumors
were 88 and 97%, respectively (p < 0.001). On multivariate analysis, MSIBC was confirmed to be associated with
higher LR rate after controlling for other variables, including surgery type. However, other reports, including
systemic therapy and greater attention to surgical margin status [103], did not show any increased rate of LR after
BCS compared with mastectomy [104]. In addition, closer adherence to guidelines emerged as a key aspect to reverse
the difference in local control and survival among UF and MSIBC groups in a multicenter study analyzing 8935
patients [105].
The reported inferior local control of MSIBC, regardless of type of treatment, can be partially attributable to
tumor extension and partly to the more aggressive nature of MSIBC, as exhibited by the properties of clones of
neoplastic cells enabling spread across the breast.
Partial breast irradiation & the risk of multicentricity
BC RT has become more and more risk adapted over recent years with a trend toward a reduction in intensity
and extent. The rationale of delivering RT to the tumor bed, so-called partial breast irradiation (PBI), is based
on evidence that most ipsilateral tumor recurrences occur in the same site as the primary BC [94,106]. While
macroscopically evident MSIBC represent an apparent contraindication to PBI, the same applies to all clinical
situations where the probability of occult MSIBC is not negligible. In fact, since the effect of PBI is limited to the
index quadrant, it is of paramount importance to select patients at low risk of harboring occult microscopic disease
in the remaining breast, so that local control is not inferior to that of WBI.
Several guidelines (American Brachytherapy Society [ABS] [107], American Society for Radiation Oncology [AS-
TRO] [108], European Society for Radiotherapy and Oncology [ESTRO] [109]) have been published to define eligible
patients. The selection criteria for the ideal candidate are based on clinical, histopathological and biomolecular
features that are well known to be associated with a low risk of LR. The ESTRO and ASTRO guidelines for
PBI include age ≥50 years, unicentric, UF pT1 (pT2 ≤30 mm for ESTRO) pN0, no lobular histology (which is
instead accepted by the ABS), without the presence of an extensive intraductal component and LVI, with negative
margins of at least 2 mm. Regarding hormonal receptors, ASTRO only requires positive expression. The literature
has clearly shown that the greater the number of risk factors, the higher the risk of LR across the breast [110,111].
Tendulkar et al. pointed out the significant association of some tumor features with additional ipsilateral disease,
such as lobular histology, pathologic T2 and AJCC stage II [112]. In particular, the exclusion of ILC in the ASTRO
and ESTRO guidelines [109] was agreed on the base of MSIBC nature of such histology and on evidence from
retrospective studies [113] and the Christie Hospital randomized trial [114], which showed an increased rate of LR
(42 vs 17%). Conversely, ABS guidelines included all invasive subtypes, alongside ILC, embracing the concept that
failure is more due to poor tumor biology rather than the type of treatment [107]. In more recent randomized trials
comparing PBI and WBI, ILC has been handled in different ways [115]: some trials excluded it from eligibility crite-
ria, such as the TARGIT, the National Institute of Oncology Hungarian, the RAPID and the IMPORT LOW trials,
while others did not. Among the published trials including ILC, the GEC-ESTRO and the University of Florence
Phase III trials and the Phase II German–Austrian trial did not show any difference related to histology [116]. In
a single institution series of patients treated with intraoperative RT with electrons comparing 252 ILC with 1921
IDC, the rate of LR was 1.96-times higher for ILC. However, difference in local control became nonsignificant
when larger intraoperative RT collimator were used, underlining the importance of an extended RT field to reach
microscopic neoplastic foci surrounding ILC [117]. With a view to improving selection, MRI is often used because
of its greater ability to identify additional neoplastic foci compared with conventional radiology. Although not
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Figure 1. Flowchart for a multidisciplinary management of multiple synchronous (multifocal or multicentric)
ipsilateral breast cancer patients.
routinely recommended in clinical practice, the use of magnetic resonance is supported by the European Society of
BC Specialists (EUSOMA) Working Group for PBI decision-making [118].
Histology & multicentricity
ILC is typically associated with more occult disease than IDC [119], as several pathological studies have documented.
Radiologically, MSIBC foci can be found up to 25% of the patients with ILC, compared with about 10% for
IDC [120]. For this reason, the safe delivery of BCS has been a matter of debate, as BCS is seen as merely debulking
and the efficacy of WBI in multiple synchronous (multifocal or multicentric) ipsilateral BC is questioned by the
expected greater tumor burden, especially when negative margins are not obtained at initial BCS. The reported
positive margin status ranged from 18 to 63% [121], especially in presence of extensive intraductal component,
larger tumor size and high grade [122] and represents an important risk factor for LR after BCS in patients without
re-excision or with positive compared with negative re-excisions [123]. Currently, there is no evidence of increased
incidence of LRs when BCS is performed and clear margins are achieved [119]. In a large French series of over
11,000 patients with long follow-up treated at the Institute Curie, ILC patients receiving BCS had similar LR and
OS rates to those affected by IDC [124], prompting discussion around the high radiosensitivity of ILC [121].
Is multicentricity an indication for postmastectomy RT?
MSIBC is not an independent risk factor of LR such as to warrant postmastectomy RT (PMRT). Therefore, MSIBC
by itself does not influence the recommendation for adjuvant RT in the mastectomy setting. The adverse patient
outcome of MSIBC can be explained by the more frequent association with axillary node involvement compared
with UF tumors with similar stage of disease [125]. In the study by Coombs and Boyages 52.1% of MSIBC had
axillary node involvement compared with 37.5% with UF BC (p = 0.007) [7]. Not only is axillary involvement
more frequent, but the nodal burden is also heavier. In the study conducted by Weissenbacher et al. [28], 30.9% of
BC patients in the MSIBC group were classified as pN2 and pN3. Some authors attributed the nodal positivity to
the total tumor load resulting in a more advanced stage [126], while others suggested that MSIBC is a heterogeneous
disease and that lymph node spread reflects the size of the more aggressive primary lesion [27]. The increased use
of PMRT and chemotherapy for MSIBC in the population of 1322 patients with T1–3 invasive BC, analyzed by
Cabioglu et al. [27], was motivated by their more advanced stage at presentation compared with UF BC. When
patients were grouped according to stage, the difference in terms of rates of systemic metastases, LR, disease-free
survival or OS between MSIBC and UF disappeared. This observation has been confirmed by other reports. In
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a group of 906 patients classified as having MSIBC and UF disease, Lynch et al. described no difference in local
control between the MSIBC and UF groups treated with BCS, mastectomy alone or PMRT [127]. There is conflict
in the literature as to differences between MSIBC and UF disease with regard to age, nuclear grade, histologic
grade, LVI, and ER and PgR status, which can be key factors in the decision making for PMRT [17,27]. The role
of PMRT in patients with one to three positive nodes after axillary dissection is controversial [128], and MSIBC
should not be considered as an additional risk factor to justify PMRT. In a small subgroup of patients analyzed in
the study by Katz et al., MSIBC in T1–2 N1a tumors was not an independent risk factor for LR [129].
Conclusion
MSIBC with heterogeneous histopathology represents a controversial clinical condition, widely debated and studied
in the literature, without an international consensus on the definition and its clinical management. The actual
incidence of MSIBC is unknown, however, the frequency is increasing due to improvements in sensitivity of imaging
and use of breast MRI for BC screening and staging. This heterogeneous disease requires particular attention in
the management, since MSIBC tends toward more aggressive biology and higher rates of nodal positivity [130].
Once MSIBC is diagnosed, surgeons need to carefully weigh up BCS versus mastectomy options to optimize
oncological safety. Mastectomy rates have increased in the last decade due in part to the diagnosis of MSIBC,
however, BCS with achievement of clear margins is feasible in selected cases. Based on the contemporary BC care
approach, the management of this heterogeneous disease warrants shared decision-making inside a multidisciplinary
team (Figure 1). In this multidisciplinary review, we considered the different faces of this rare disease offering practical
guidance for clinicians after a diagnosis of MSIBC.
We are strongly convinced that MSIBC presents a different genetic pathway in comparison to UF BC. Further
studies, as the Next-Generation Sequency, could compare somatic genetic results between UF and multicentric BC,
to identify some possible tumor differences.
Future perspective
The current trend of scientific research in MSIBC’s management is showing that, thanks to the increasingly early
breast cancer clinical detection and targeted therapies development, LR rate and cosmetic outcome after BCS for
MSIBC appear similar to those of UF neoplasia, at the same stage. Near future looks at results from prospective and
clinical randomized trials, already ongoing, analyzing the BCS validity respect to mastectomy and the significant
role of systemic treatments based on the biology of every multiple lesions, in terms of LR and OS rate. A novel
rigorous look to genetic pattern’s heterogenicity of each different focus will represent an even more targeted and
specific therapeutic approach for MSIBC.
Executive summary
• Multicentric breast cancer with heterogeneous histopathology: a multidisciplinary review.
• The new acquisitions in imaging, thanks to the introduction of the ultrasound and, more recently, of MRI in the
diagnostic route of breast cancer, associated with increased screening, have allowed obtaining greater sensitivity
in multiple synchronous (multifocal or multicentric) ipsilateral breast cancers (MSIBC) diagnosis.
• There are not so many studies about heterogeneity of each focus in MSIBC, in particular in terms of different
histopathology: various results and motley conclusions emerge from few studies addressed to analyze histological
and immunohistochemical features of tumor foci in MSIBC.
• There is no a standard method in surgical management of MSIBC.
• The choice to perform breast conservation surgery (BCS) for MSIBC in the last years has improved, thanks also to
the support of oncoplastic technique, even if there are not clinical evidence studies on quality of life after
mammoplasty in BCS compared with mastectomy.
• In the literature, there are not significative prospective cohort studies nor randomized trials comparing BCS with
mastectomy, analyzing as primary end point locoregional recurrence in MSIBC: indeed, most of those are
retrospective cohort studies.
• In a clinically negative axilla, sentinel lymphnode biopsy is a feasible, safe and accurate surgical procedure in
axillary staging in MSIBC. No difference in lymph node recurrence or overall survival has been found among
patients undergoing sentinel lymphnode biopsy for MSIBC versus unifocal disease.
• Technological improvements in radiotherapy and the increasingly clinical value of target neoadjuvant/adjuvant
therapies could support a more conservative surgical management.
• Multidisciplinary approach is crucial in patient’s selection for surgical and adjuvant treatments in the case of
MSIBC, in the future also supported by novel genetic researches.
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